After 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership.
Eli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the market with an anti-amyloid drug for Alzheimer's disease, and its preparing the ground with a restructur
GlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer – will retain the top job at the business after it is hived off
Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech's chief medical officer Bill Grossman to a new role as its head of oncology
GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics.